Inhibition of CKS1B impairs STAT3 signaling and suppresses PD-L1 expression, suggesting a novel therapeutic axis for targeting aggressive thyroid cancers (43) (Figure 1). This evidence concerns the gene CD274 and thyroid gland carcinoma.